TABLE 3

The Effect of VAS by Vaccine at Enrollment on All-Cause Mortality, Overall and by Gender

Rate per 1000 PYRS# (Deaths/PYRS)MRR (95% Confidence Interval)aTest of Interaction Between VAS and Genderb
Vitamin APlacebo
Live
 MV/MV+YFn = 1547n = 1614
  All13.2 (10/760)10.1 (8/791)1.29 (0.51–3.28)
  Boys17.9 (7/391)7.4 (3/405)2.40 (0.62–9.29)0.18
  Girls8.1 (3/368)13.0 (5/386)0.62 (0.15–2.61)
Inactivated
 DTP or pentavalentn = 1082n = 1072
  All28.3 (15/530)26.6 (14/527)1.06 (0.51–2.20)
  Boys33.0 (9/273)15.0 (4/267)2.16 (0.67–7.03)0.11
  Girls23.3 (6/257)38.5 (10/260)0.61 (0.22–1.69)
Live and inactivated
 MV/MV+YF + DTP/Pentavalentn = 791n = 819
  All20.6 (8/389)40.1 (16/399)0.52 (0.22–1.21)
  Boys32.9 (6/182)20.2 (4/198)1.66 (0.47–5.89)0.02
  Girls9.7 (2/206)59.9 (12/200)0.16 (0.04–0.73)
  • Excluding 402 children who received OPV only (4 deaths; 3 VAS: 2 boys + 1 girl, 1 Placebo: boy), 171 children receiving YF only (3 deaths; All placebo: 1 boy + 2 girls), 18 children receiving DTP + YF (2 deaths, both VAS: boys + girls), 23 children receiving pentavalent + YF (0 deaths); follow-up for 6 months. #, person-years of observation.

  • a Analyzed by using Cox proportional-hazards models with age as underlying time scale.

  • b Tested by using Wald test.